Compare McKesson Corporation (MCK) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard Total World Stock Index Fund ETF — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while Vanguard Total World Stock Index Fund ETF trades at $161.12. The key difference: McKesson Corporation pays a 0.43% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | VT | |
|---|---|---|
Market Cap | $102.58B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $161.30 |
52-Week Low | $659.01 | $132.19 |
Enterprise Value | $109.12B | — |
Dividend Yield | 0.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Vanguard Total World Stock ETF (VT) trades at $161.3, up 0.86% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad global diversification across over 10,000 stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning adjustments, while news highlights its role in global portfolios amid trade policy uncertainty.
VT presents a long-term diversification opportunity with low-cost global equity exposure, though near-term risks include trade war volatility and seasonal choppiness. The neutral oscillator signals and high short-term RSI suggest potential consolidation, but strong institutional interest supports its core holding appeal for risk-conscious investors seeking worldwide market access.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
